SEC Form 4 · accession 0001104659-15-011689
Vitae Pharmaceuticals, Inc · VTAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Gregg
Officer — Chief Science Officer
Period of report
Feb 13, 2015
Accepted (ET)
Feb 18, 2015 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157602
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $14.40 | Feb 13, 2015 | A | 21,250 | A | — | Feb 13, 2025 | Common Stock | 21,250 | 21,250 | D |
Explanation of responses
- F1This option shall vest with respect to 25% of the shares of stock which are subject to this option on February 13, 2016 (the "Initial Vesting Date") and 2.083% of the shares of stock which are subject to this option monthly following the Initial Vesting Date.
Remarks
Exhibit List Exhibit 24 - Power of Attorney